Jyong Biotech shares rise 12.62% intraday after Phase II trial of MCS-8 shows 27.3% prostate cancer incidence reduction and Vietnam MoU expands Asian partnerships for urology treatments.

Jyong Biotech surged 12.62% intraday, driven by the successful completion of Phase II clinical trials for its lead candidate MCS-8, which demonstrated a 27.3% reduction in prostate cancer incidence compared to a placebo and revealed novel lipid-regulating properties. The company also signed a memorandum of understanding in Vietnam on December 6, 2025, to expand regional partnerships and strengthen its commercial presence in Asia’s urology treatment market. As a science-driven biotechnology firm, Jyong Biotech specializes in developing plant-based therapeutics for urological diseases and is expanding key markets in Korea and Vietnam through strategic collaborations.